Every year, ~3,500 children are diagnosed with Acute Lymphoblastic Leukemia and ~25,000 adults are diagnosed with Diffuse Large B-Cell Lymphoma. 10% of these children, and 50% of these adults who do not respond to upfront therapies are faced with limited treatment options and low survival rates. Over the past few years, Cell & Gene therapies for these diseases have come to market, bringing new hope to patients, caregivers and HCP's alike. There is still a large unmet need, and at Novartis we are reimagining medicine to continue to bring this innovative therapy to not only these patients, but those with other B-cell malignancies as well.
The role will be responsible to drive all aspects of Market Access strategy development and execution for first-of-their-kind Chimeric Antigen Receptor T-cell (CAR-T) Therapy brands from pre-launch strategy development through commercialization and life-cycle management
The Executive Director, Head US CAR-T Market Access will be responsible for the following: Develop a US integrated Pricing, Contracting, Market Access & Payer strategy, creating innovative market access solutions and driving payer policy / advocacy for cell therapy Deliver product differentiation most relevant to public and private payers (e.g. target patient population, clinical end-points, clinical comparators, outcome measures, utility instruments, Health Economics data, etc.)
Ensure that at launch, Novartis brands are supported by a robust payer value proposition including 3 core elements - 'Value for money' story, strong evidence package and an appropriate pricing strategy maximizing the life-time value of the brand (including existing and future evidence to justify and maintain price)
Ensure close alignment between insights into payer evidence needs, plans to generate evidence (clinical, HEOR, etc.) to support payer value proposition and pricing strategy
Represent Market Access & Payer perspective at appropriate OBU US and C&G forums
Be accountable for the Market Access & Payer perspective being appropriately integrated in the overarching product development, medical affairs and commercial strategy
In coordination with OBU US and C&G Market Access leadership, represent Novartis to the payer/HTA community and in turn articulate payer needs/preferences to Novartis (across the decision making forums and internal teams